In vivo, delivery of anti-NOX4-siRNA encapsulated in heart-targeting small extracellular vesicles improved LV contractile function and reduced cardiac hypertrophy in C57BL/6 mice chronically infused with angiotensin II [106] (Table 4). Here, AGT is linked to cardiac hypertrophy.